Cassie Jung sold $474k of AQST
Chief Operating Officer at Aquestive Therapeutics, Inc.. 67,575 shares at an average of $7.01, traded Oct 15, 2025, filed Oct 17, 2025.
Score components
- +20RoleCOO
- +17Trade size$474k at market
- +5Share of holdings soldSold 22% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -23.9%, 3m -53.2%, 6m -39.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001214659-25-015048, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 15, 2025 | MOption exercise Common Stock10b5-1 | +25,000 | $3.10 | $78k | 308,346 | Oct 17, 2025 |
| Oct 15, 2025 | SOpen-market sale Common Stock10b5-1 | -67,575 | $7.01 | $474k | 240,771 | Oct 17, 2025 |
| Oct 15, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 0 | Oct 17, 2025 |
Related signals
Other insiders at Aquestive Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Aquestive Therapeutics, Inc. | Daniel Barber President and CEO | $120k 25,000 shares | -4% | |
| 0Weak | Aquestive Therapeutics, Inc. | Sherry Korczynski Chief Commercial Officer | $46k 8,750 shares | -4% | |
| 15Weak | Aquestive Therapeutics, Inc. | Daniel Barber President and CEO | $107k 25,000 shares | -4% | |
| 15Weak | Aquestive Therapeutics, Inc. | Daniel Barber President and CEO | $100k 25,000 shares | -4% | |
| 19Weak | Aquestive Therapeutics, Inc. | Julie Krop director | $125k 25,000 shares | -100% | |
| 23Weak | Aquestive Therapeutics, Inc. | Daniel Barber President and CEO | $104k 25,000 shares | -4% | |
| 11Weak | Aquestive Therapeutics, Inc. | Daniel Barber President and CEO | $35k 8,257 shares | -1% | |
| 52Moderate | Aquestive Therapeutics, Inc. | Cassie Jung Chief Operating Officer | $191k 45,791 shares | -14% | |
| 38Weak | Aquestive Therapeutics, Inc. | Sherry Korczynski Chief Commercial Officer | $66k 15,741 shares | -6% | |
| 55Moderate | Aquestive Therapeutics, Inc. | A Ernest Toth Jr Chief Financial Officer | $243k 58,254 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.